Purchase Order VA580N15449
Award Date 11/16/10
Potential Completion Date 11/16/10
Potential Value $3.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Scottsdale, AZ 85257, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award, valued at $6,937.52, was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is a firm-fixed-price purchase order, with an ultimate completion date of March 18, 2011. No set-aside...
- This federal contract award, valued at $3,645.14, was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was issued as a purchase order under Regenesis Biomedical's existing General Services Administration (GSA)...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company that develops and markets noninvasive regenerative medicine products. The $4,820.98 firm-fixed-price purchase order is for Regenesis Biomedical's Provant Therapy System, a patented medical device indicated for palliative treatment of post-operative pain and edema. The contract has a performance period through March 16, 2011 and was not set aside for...
- This federal contract award to Regenesis Biomedical Inc. was made by the Department of Veterans Affairs (VA) for the provision of the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The $3,645.14 firm fixed-price purchase order contract has a completion date of June 16, 2011. Regenesis Biomedical is the prime contractor providing its proprietary medical device directly to the VA, with no subcontractors...
- This federal contract award, valued at $7,145.55, was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. This contract appears to be a purchase order under Regenesis Biomedical's existing GSA Schedule 65-II-A contract...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the provision of the Provant Therapy System, a patented noninvasive regenerative medicine product. The $7,142.85 firm-fixed-price purchase order contract is for the palliative treatment of post-operative pain and edema. The contract is part of Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A for medical equipment and...
- This federal contract award, valued at $4,820.98, was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The contract is for the provision of the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical, to VA medical facilities. The contract was awarded as a purchase order under Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $7,142.85 firm fixed-price purchase order contract is for the provision of Regenesis Biomedical's Provant Therapy System, a patented noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with any set-aside designations. Regenesis Biomedical,...
- This is a federal contract award from the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company. The $7,055.10 firm-fixed-price purchase order is for the company's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has no set-aside designation and was awarded on December 16, 2010, with a completion date of January 16, 2011. Regenesis Biomedical, the...
- This federal contract award, valued at $7,055.10, was issued by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract does not have a set-aside designation and is structured as a firm-fixed-price purchase order. Regenesis Biomedical...